Daiken Biomedical Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	1,783	1,362	1,190	884.97
Revenue Growth (YoY)	42.69%	14.45%	34.52%	-
Cost of Revenue	633.66	506.17	376.66	271.66
Gross Profit	1,149	856.22	813.76	613.3
Selling, General & Admin	864.12	696.26	601.78	493.5
Research & Development	11.34	10.16	7.82	7.36
Operating Expenses	876.35	707.3	609.61	500.87
Operating Income	272.88	148.92	204.15	112.44
Interest Expense	-1.14	-6	-3.36	-1.18
Interest & Investment Income	18.23	28.43	2.87	0.2
Currency Exchange Gain (Loss)	-45.51	-31.85	-8.39	-1.92
Other Non Operating Income (Expenses)	89.67	0.11	0.08	0.01
Pretax Income	334.13	139.6	195.35	109.54
Income Tax Expense	65.5	33.02	35	19.36
Net Income	268.63	106.58	160.35	90.17
Net Income to Common	268.63	106.58	160.35	90.17
Net Income Growth	116.53%	-33.53%	77.83%	-
Shares Outstanding (Basic)	61	44	22	16
Shares Outstanding (Diluted)	61	44	22	16
Shares Change (YoY)	77.82%	95.20%	44.34%	-
EPS (Basic)	4.37	2.43	7.16	5.80
EPS (Diluted)	4.37	2.43	7.13	5.79
EPS Growth	21.56%	-65.93%	23.14%	-
Free Cash Flow	295.15	50.5	105.21	41.58
Free Cash Flow Per Share	4.80	1.15	4.68	2.67
Dividend Per Share	9.519	4.033	4.860	4.170
Dividend Growth	95.87%	-17.02%	16.55%	-
Gross Margin	64.46%	62.85%	68.36%	69.30%
Operating Margin	15.30%	10.93%	17.15%	12.71%
Profit Margin	15.07%	7.82%	13.47%	10.19%
Free Cash Flow Margin	16.55%	3.71%	8.84%	4.70%
EBITDA	279.28	153.13	205.07	112.54
EBITDA Margin	15.66%	11.24%	17.23%	12.72%
D&A For EBITDA	6.4	4.21	0.92	0.1
EBIT	272.88	148.92	204.15	112.44
EBIT Margin	15.30%	10.93%	17.15%	12.71%
Effective Tax Rate	19.60%	23.65%	17.91%	17.68%
Advertising Expenses	-	380.08	383.45	329.81

Source: S&P Global Market Intelligence. Standard template. Financial Sources.